Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | ΙP |
|--|----|
|--|----|

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Wong Brian Russell          |  |  |   |                                   | 2. Issuer Name and Ticker or Trading Symbol RAPT Therapeutics, Inc. [ RAPT ] |  |      |  |      |                    |   |  | Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner |   |  |  |  |
|---|--|--|---|-----------------------------------|--|--|------|--|------|--------------------|---|--|---|---|--|--|--|
| (Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC. 561 ECCLES AVENUE |  |  |   |                                   | 3. Date of Earliest Transaction (Month/Day/Year) 10/30/2019                  |  |      |  |      |                    |   |  |   | C Officer (give title Other below)  President and CEO   |  |  | pecify   |
| (Street) SOUTH FRANCI   | SCO C.   |  | 94080<br>(Zip)  | 4.                                | 4. If Amendment, Date of Original Filed (Month/Day/Year)                     |  |      |  |      |                    |   |  | e)<br>X For<br>For  | ral or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person |  |  |  |
|   |  | Tab  | le I - Non-D  | Perivativ                         | e Se   | curities   | s Ac | quired, D  | Disp | osed o             | f, or Be  | neficia                                | lly Own   | ed  |  |  |  |
| Date  |  |  |   | Transaction<br>ate<br>lonth/Day/Y | Execution Date,  |  |      | Transaction Disposed Code (Instr. 5)                           |      |                    | ties Acquired (A) o<br>d Of (D) (Instr. 3, 4 a  |  | d Secur<br>Bene   | icially<br>d Following  | es Form<br>ally (D) o<br>Following (I) (Ir   |  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)  |
|   |  |  |   |                                   |  |  |      | Code   | V    | Amount             | (A) or<br>(D)   |  | Trans   | ction(s)<br>3 and 4)  |  |  | ,iiisti. 4)  |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |   |                                   |  |  |      |  |      |                    |   |  |   |   |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date<br>if any<br>(Month/Day/Ye | Code                              |  | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr.<br>3, 4 and 5) |      | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |      |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   | derivativ<br>Securitie<br>Benefici<br>Owned<br>Followin<br>Reporte<br>Transac   | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |  |  |   | Code                              | v  | (A)  | (D)  | Date<br>Exercisable  |      | expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |   |  |  |  |
| Stock<br>Option<br>(right to<br>buy)                                  | \$12   | 10/30/2019                                 |   | A                                 |  | 83,333   |      | (1)  | 1    | 0/29/2029          | Common<br>Stock   | 83,333                                 | \$0.00  | 83,3  | 33   | D  |  |

## **Explanation of Responses:**

1. Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.

## Remarks:

/s/ Karen C. Lam, attorney-in-

fact for Brian Wong, M.D.,

11/01/2019

Date

Ph.D.

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.